巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Qiagen NV

QGEN
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Qiagen NV - 延遲價格・最後更新於 26/01 12:15
最高位
48.300
最低位
47.320
開市價
--
前收市價
47.780
成交量(千)
20.57
成交額(百萬)
9.09
買入
--
賣出
--
每手股數
--
市值(百萬)
10,778.00
市盈率
18.590
息率
--
差價
--
52週高低
59.000 - 45.580
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Qiagen NV
證券代碼
QGEN.US
所屬板塊
Diagnostics & Research
公司業務
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates over 85% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (44% of 2020 sales), followed by EMEA (36%) and Asia-Pacific (19%).
發行量
228638000
公司總部
Hulsterweg 82
公司網址
https://www.qiagen.com
公司電郵
sarah.fakih@qiagen.com
公司電話
+31 773556600

快而精醫藥(QGEN.IS)與QIAcuity生態系統的合作

格隆匯·
快而精醫藥(QGEN.IS)與QIAcuity生態系統的合作

快而精醫藥(QGEN.IS)與QIAcuity生態系統的合作

格隆匯·
快而精醫藥(QGEN.IS)與QIAcuity生態系統的合作

關於

Qiagen NV(QGEN.US)所屬的行業板塊為Diagnostics & Research。
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates over 85% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (44% of 2020 sales), followed by EMEA (36%) and Asia-Pacific (19%).
詳細公司背景可參考: https://www.qiagen.com